Experimental evolution of cefiderocol resistance in Pseudomonas aeruginosa

Cefiderocol is a novel and promising cephalosporin approved for treating severe infections caused by Gram-negative bacteria with limited therapeutic options. One of the primary targets of cefiderocol is Pseudomonas aeruginosa, a significant opportunistic Gram-negative pathogen. In this study, we uti...

Full description

Bibliographic Details
Published in:	Heliyon
Main Authors:	Igor Chebotar, Konstantin Kuleshov, Julia Bocharova, Nikolay Mayanskiy
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Subjects:	Pseudomonas aeruginosa Antibiotic resistance Cefiderocol Mutation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844025020675

Similar Items

New mutations in genes associated with cefiderocol resistance in a clinical isolate of Pseudomonas aeruginosa
by: Bocharova Yu.A., et al.
Published: (2023-12-01)

The phenomenon of changing aztreonam susceptibility in Pseudomonas aeruginosa during formation of colistin resistance in vitro
by: Bocharova Yu.A., et al.
Published: (2025-03-01)

Genetic Alternatives for Experimental Adaptation to Colistin in Three <i>Pseudomonas aeruginosa</i> Lineages
by: Igor Chebotar, et al.
Published: (2024-05-01)

Evaluation of antibiofilm activity of cefiderocol alone and in combination with imipenem against Pseudomonas aeruginosa
by: Caterina Ferretti, et al.
Published: (2024-06-01)

In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients
by: Marguerite L. Monogue, et al.
Published: (2023-12-01)

An Assessment Of Cefiderocol's Synergistic Effects With Eravacycline, Colistin, Meropenem, Levofloxacin, Ceftazidime/Avibactam, And Tobramycin Against Carbapenem-Resistant Pseudomonas Aeruginosa
by: Bekir Özer, et al.
Published: (2024-12-01)

Cefiderocol activity against planktonic and biofilm forms of β-lactamase-producing pseudomonas aeruginosa from people with cystic fibrosis
by: Giorgia Fabrizio, et al.
Published: (2025-06-01)

Performance of disc diffusion and E-test on different Muller-Hinton agar media plates and ComASPⓇ and Bruker UMICⓇ Cefiderocol Microdilution Panels for Cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa
by: Stefano Mancini, et al.
Published: (2024-12-01)

The Efficacy of Topical Cefiderocol Treatment of Experimental Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Keratitis Is Dependent upon the State of the Corneal Epithelium
by: Eric G. Romanowski, et al.
Published: (2024-10-01)

SUSCETIBILIDADE DE CEFIDEROCOL ENTRE PSEUDOMONAS AERUGINOSA E COMPLEXO ACINETOBACTER BAUMANNII (CAB) EM HOSPITAL TERCIÁRIO DE PORTO ALEGRE
by: Deise Reis Carvalho, et al.
Published: (2023-10-01)

Comparison of Different Methods for Assaying the In Vitro Activity of Cefiderocol against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Strains: Influence of Bacterial Inoculum
by: Celia García-Rivera, et al.
Published: (2024-07-01)

Cefiderocol susceptibility of Stenotrophomonas maltophilia species complex and carbapenem-resistant Pseudomonas aeruginosa isolates from blood cultures at a university hospital in Tokyo, Japan
by: Wataru Aoki, et al.
Published: (2025-09-01)

TROJAN-MDR: in vitro activity of cefiderocol and comparators against multidrug-resistant Enterobacterales and Pseudomonas aeruginosa strains in Southern France, evaluation of available testing methods performances
by: Massinissa Benyahia, et al.
Published: (2025-03-01)

Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway
by: Luise Brakert, et al.
Published: (2023-09-01)

In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals
by: John H. Kimbrough, et al.
Published: (2024-11-01)

Novel PiuC, PirA, and PiuA mutations leading to in vivo cefiderocol resistance progression in IMP-16- and KPC-2-producing Pseudomonas aeruginosa from a leukemic patient
by: Joaquim Viñes, et al.
Published: (2025-03-01)

Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections
by: Amer El Ghali, et al.
Published: (2024-02-01)

Activity of Ceﬁderocol and Other New Antibiotics Against Extensively Drug-Resistant <i>Klebsiella pneumoniae</i> Strains
by: E. V. Karpova, et al.
Published: (2023-02-01)

Antibiosis resistant of Pseudomonas aeruginosa isolated from different clinical specimens
by: Siham Sh. AL-Salihi, et al.
Published: (2014-12-01)

Analysis of <i>Pseudomonas aeruginosa</i> Isolates from Patients with Cystic Fibrosis Revealed Novel Groups of Filamentous Bacteriophages
by: Peter Evseev, et al.
Published: (2023-11-01)

Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria
by: Russell E. Lewis, et al.
Published: (2024-08-01)

Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study
by: Alexandre Bleibtreu, et al.
Published: (2021-01-01)

Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant <i>Pseudomonas aeruginosa</i> Bloodstream Infections and/or Hospital-Acquired Pneumonia
by: Milo Gatti, et al.
Published: (2022-12-01)

Azithromycin represses evolution of ceftazidime/avibactam resistance by translational repression of rpoS in Pseudomonas aeruginosa
by: Congjuan Xu, et al.
Published: (2025-05-01)

Colonisation with Pseudomonas aeruginosa and antibiotic resistance patterns in COPD patients
by: Kathrin Engler, et al.
Published: (2012-01-01)

Bacteriolytic Activity study of Aerophage on Pseudomonas aeruginosa
by: Zahraa Jaafar Jameel
Published: (2018-06-01)

Bacteriolytic Activity study of Aerophage on Pseudomonas aeruginosa
by: Zahraa Jaafar Jameel
Published: (2018-06-01)

The prevalence of Pseudomonas aeruginosa and multidrug resistant Pseudomonas aeruginosa in healthy captive ophidian
by: Andrea Sala, et al.
Published: (2019-04-01)

The frequency of Pseudomonas aeruginosa bacteria with some pathogenic bacteria in burns injuries and study their resistance to antibiotics
by: Mohamed B. Khorsheed, et al.
Published: (2017-03-01)

Molecular Detection of Psts Antibiotic-Resistant Gene in Pseudomonas aeruginosa Isolates
by: Fatima Rheem Wadi, et al.
Published: (2024-07-01)

Cefiderocol - a promising new antibiotic for the antibiotic-resistant pathogens of the highest epidemiological priority
by: Karol Lorenc Lorenc, et al.
Published: (2019-05-01)

Risk factors for healthcare-associated infections caused by cefepime-resistant Pseudomonas aeruginosa
by: Folić Marko M., et al.
Published: (2020-01-01)

The Use of Cefiderocol as Salvage Therapy in an Infant Receiving ECMO and Continuous Renal Replacement Therapy
by: Stefania Mercadante, et al.
Published: (2023-12-01)

Phenotypic heterogeneity unveils a negative correlation between antibiotic resistance and quorum sensing in Pseudomonas aeruginosa clinical isolates
by: Xiting Yang, et al.
Published: (2024-02-01)

Mutational Analysis of Colistin-Resistant <i>Pseudomonas aeruginosa</i> Isolates: From Genomic Background to Antibiotic Resistance
by: Telma De Sousa, et al.
Published: (2025-04-01)

Dissemination of Aminoglycosides Resistance in Pseudomonas Aeruginosa Isolates in Al-Nasiriya Hospitals Pseudomonas Aeruginosa
by: Ali A. Abdul-Wahid, et al.
Published: (2015-04-01)

Confirmatory identification and antibiotics resistance profiling of Pseudomonas aeruginosa: a laboratory-based study
by: Hafsa Abdulhamid Abdulsalam
Published: (2025-01-01)

The Prevalence of Cephalosporins resistance in Pseudomonas aeruginosa isolated from clinical specimens in Basra, Iraq
by: Zeina MM Alkhulaifi, et al.
Published: (2023-04-01)

Tolerance and Resistance of Pseudomonas aeruginosa Biofilms to Antimicrobial Agents—How P. aeruginosa Can Escape Antibiotics
by: Oana Ciofu, et al.
Published: (2019-05-01)

Effect of QRDR Mutations on Ciprofloxacin Resistance in Clinical Isolates of Pseudomonas aeruginosa
by: Roqiyeh Nouri, et al.
Published: (2016-07-01)